世界睡眠医学杂志2025，Vol.12Issue(9)：1941-1945,5.DOI:10.3969/j.issn.2095-7130.2025.09.009
布地格福对COPD-OSA重叠综合征患者夜间低氧血症的改善作用
Effect of Budigefor on Nocturnal Hypoxemia in Patients with COPD-OSA Overlap
摘要
Abstract
Objective:To explore the effect of Budigefor on improving nocturnal hypoxemia in patients with chronic obstructive pulmonary disease(COPD)-obstructive sleep apnea(OSA)overlap.Methods:A total of 100 patients with COPD-OSA overlap who were admitted to Dafeng People's Hospital,from January to December 2024 were selected as the study subjects.They were randomly divided into a control group and an observation group,with 50 cases in each group.All patients received conventional treatment,and the control group additionally received budesonide intervention and the observation group received Budigefor inter-vention.The average pulse oximetry saturation(SpO2)during the entire nocturnal sleep and the longest duration of hypoxemia were recorded by polysomnography(PSG)and to simultaneously record parameters,including nasal/oral airflow and respiratory movements.Brain activity was analyzed to record sleep onset time,start of first rapid eye movement(REM)sleep,REM latency,a-wakening events during sleep,and the sleep fragmentation index.The Pittsburgh Sleep Quality Index(PSQI)was used to assess patients' nocturnal sleep quality and Epworth Sleepiness Scale(ESS)were used to assess daytime excessive sleepiness.Venous blood samples were collected before and after sleep,and serum IL-6 concentrations were measured by enzyme-linked immunosor-bent assay(ELISA).The COPD Assessment Test(CAT)was employed to evaluate the improvement in clinical symptoms and quality of life.The 36-item Medical Outcomes Study Short-Form Health Survey(SF-36)was used to evaluate the quality of life.Results:After the intervention,the observation group showed significantly higher average nocturnal SpO2 and lowest SpO2 compared to the control group,while the longest duration of hypoxemia,apnea-hypopnea index,and oxygen desaturation index were significantly lower in the observation group,with significant differences between the two groups(P＜0.05).The observation group exhibited significantly higher slow-wave sleep proportion and significantly lower REM latency and sleep fragmentation index com-pared to the control group,with statistically significant differences between the two groups(P＜0.05).After the intervention,PSQI and ESS scores in the observation group were significantly lower than those in the control group,with statistically significant differ-ences between the two groups(P＜0.05).The diurnal difference in interleukin-6(IL-6)and nocturnal 8-isoprostane in the obser-vation group were significantly lower than those in the control group,with statistically significant differences(P＜0.05).The CAT and mMRC scores in the observation group after the intervention were significantly lower than those in the control group,while the physical function score on the SF-36 was significantly higher,with all differences between the two groups being statistically signifi-cant(P＜0.05).Conclusion:Budigefor can improve nocturnal hypoxemia in patients with COPD-OSA overlap,enhance sleep quality,reduce nighttime inflammatory-oxidative stress responses,and relieve the disease's adverse effects on patients'quality of life.关键词
布地格福/COPD-OSA重叠综合征/低氧血症/慢性阻塞性肺疾病-阻塞性睡眠呼吸暂停Key words
Budigefor/COPD-OSA overlap/Nocturnal hypoxemia/Chronic obstructive pulmonary disease-obstructive sleep ap-nea分类
医药卫生引用本文复制引用
郭小乐,顾小雷..布地格福对COPD-OSA重叠综合征患者夜间低氧血症的改善作用[J].世界睡眠医学杂志,2025,12(9):1941-1945,5.基金项目
盐城市卫生健康委科研项目(YK2024238) （YK2024238）
